These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11112116)

  • 1. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. The American-Italian AATD Study Group.
    Gottlieb DJ; Luisetti M; Stone PJ; Allegra L; Cantey-Kiser JM; Grassi C; Snider GL
    Am J Respir Crit Care Med; 2000 Dec; 162(6):2069-72. PubMed ID: 11112116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation.
    Ma S; Lin YY; He J; Rouhani FN; Brantly M; Turino GM
    COPD; 2013 Aug; 10(4):473-81. PubMed ID: 23560990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha-1-antitrypsin-deficient humans.
    Stone PJ; Morris TA; Franzblau C; Snider GL
    Respiration; 1995; 62(2):76-9. PubMed ID: 7784713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary excretion of desmosine (elastin cross-links) in subjects with PiZZ alpha-1-antitrypsin deficiency, a phenotype associated with hereditary predisposition to pulmonary emphysema.
    Pelham F; Wewers M; Crystal R; Buist AS; Janoff A
    Am Rev Respir Dis; 1985 Oct; 132(4):821-3. PubMed ID: 3876794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the Normative Aging Study.
    Gottlieb DJ; Stone PJ; Sparrow D; Gale ME; Weiss ST; Snider GL; O'Connor GT
    Am J Respir Crit Care Med; 1996 Nov; 154(5):1290-5. PubMed ID: 8912738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
    Tonelli AR; Brantly ML
    Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial.
    Campos MA; Geraghty P; Holt G; Mendes E; Newby PR; Ma S; Luna-Diaz LV; Turino GM; Stockley RA
    Am J Respir Crit Care Med; 2019 Aug; 200(3):318-326. PubMed ID: 30965011
    [No Abstract]   [Full Text] [Related]  

  • 8. Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome?
    Abboud RT; Ford GT; Chapman KR
    Treat Respir Med; 2005; 4(1):1-8. PubMed ID: 15725045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-1-antitrypsin and other proteinase inhibitors.
    Miravitlles M
    Curr Opin Pharmacol; 2012 Jun; 12(3):309-14. PubMed ID: 22365503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Identifying Urine/Serum Biomarkers in Alpha-1 Antitrypsin Deficiency for More Personalized Future Treatment Strategies.
    Ferrarotti I; Corsico AG; Stolk J; Ottaviani S; Fumagalli M; Janciauskiene S; Iadarola P
    COPD; 2017 Feb; 14(1):56-65. PubMed ID: 27827549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of inhaled human α-1 antitrypsin in people with α-1 antitrypsin deficiency-related emphysema.
    Franciosi AN; McCarthy C; McElvaney NG
    Expert Rev Respir Med; 2015 Apr; 9(2):143-51. PubMed ID: 25598013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
    Chapman KR; Chorostowska-Wynimko J; Koczulla AR; Ferrarotti I; McElvaney NG
    Int J Chron Obstruct Pulmon Dis; 2018; 13():419-432. PubMed ID: 29430176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-1 antitrypsin augmentation therapy.
    Wewers MD; Crystal RG
    COPD; 2013 Mar; 10 Suppl 1():64-7. PubMed ID: 23527997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers in Alpha-1 Antitrypsin Deficiency Chronic Obstructive Pulmonary Disease.
    Turino GM; Ma S; Cantor JO; Lin YY
    Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S336-40. PubMed ID: 27564670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of alpha-1 antitrypsin deficiency.
    Ranes J; Stoller JK
    Semin Respir Crit Care Med; 2005 Apr; 26(2):154-66. PubMed ID: 16088434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.
    Stockley RA; Bayley DL; Unsal I; Dowson LJ
    Am J Respir Crit Care Med; 2002 Jun; 165(11):1494-8. PubMed ID: 12045122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).
    Hill AT; Campbell EJ; Bayley DL; Hill SL; Stockley RA
    Am J Respir Crit Care Med; 1999 Dec; 160(6):1968-75. PubMed ID: 10588615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
    Campos MA; Lascano J
    Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Obstructive Pulmonary Disease. A Biomarker and a Potential Therapy.
    Turino GM
    Ann Am Thorac Soc; 2018 Feb; 15(Suppl 1):S15-S17. PubMed ID: 29461896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: from pharmacokinetic analysis to individualizing therapy.
    Zamora NP; Pla RV; Del Rio PG; Margaleff RJ; Frias FR; Ronsano JB
    Ann Pharmacother; 2008 May; 42(5):640-6. PubMed ID: 18413692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.